Weight-loss drug developer Kailera Therapeutics' shares surged 62.5% in their Nasdaq debut on Friday after closing a $625 ...
As many of us know, keeping weight in check can be hard. National data reflect that reality. Rates of overweight and obesity in the U.S. have steadily climbed since the early 1980s. The impact on ...
At a moment when there's a lot of political attention around questions of affordability, rising health care costs are a ...
The trading gives Waltham-based Kailera a market value of almost $3.1 billion based on the outstanding shares listed in its ...
The GLP-1 weight loss drugs revolutionizing the treatment of obesity, diabetes and a slew of other diseases come with a major ...
A group of global experts is proposing a new way to define and diagnose obesity, reducing the emphasis on the controversial ...
Eli Lilly's newly launched weight-loss pill was prescribed 1,390 times in the U.S. in its first week of sales, according to ...
Queen Latifah, 56, looked gorgeous as she made rare public appearance to accept an important award at CinemaCon 2026.
One quick intervention won't drastically lower heart disease, obesity and diabetes rates. It will take a long game and a ...
Metabolic disease is reshaping care delivery and costs, with experts at the Academy of Managed Care Pharmacy (AMCP) 2026 ...
"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...
The trial of 2,700 patients with increased cardiovascular risk showed that Foundayo lowered the risk of heart attack, stroke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results